| Contact Us | About UsAdvertisement | 
Weather Forecast


EU AstraZeneca Diabetic Medicine approved
Tuesday, 29 November 2011
AstraZeneca and Bristol-Myers Squibb and has received approval for its drug komboglyze by the EU Commission.

The approval means that it would use in all 27 member countries. The agent is used to treat type 2 diabetes as an adjunct to diet and exercise in some patients aged 18 years.

In other development, AstraZeneca PLC announced that on 28 November 2011, it purchased for cancellation 771,388 ordinary shares of AstraZeneca PLC at a price of 2806 pence per share.
Some of these shares were purchased under the terms of the previously announced irrevocable, non-discretionary share repurchase programme for the period 3 October 2011 to 16 December 2011.
Upon the cancellation of these shares, the number of shares in issue will be 1,303,883,230.
By Scancomark.se Team

| Print Friendly and PDF| Write to the editor | Complaint about this article | Make a Comment |
Swedband to cut workers more than previously thought

What do you think about the above article? Please leave us a comment and reaction. Thank you.
  • Should be Empty: